EUVIMEDEUVIMED entdecken
Crossref

A Novel Myricetin Derivative with Anti-cancer Properties Induces Cell Cycle Arrest and Apoptosis in A549 Cells

Hangtian Zhou, Lingling Xu, Yan Shi, Shihui Gu, Nan Wu, Fei Liu, Yinjiu Huang, Zhongqing Qian, Wei Xue, Xiaojing Wang, Fuliang Chen

Biological and Pharmaceutical Bulletin · 01.01.2023 · 46 (1) · 42-51

DOI: 10.1248/bpb.b22-00483 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biological and Pharmaceutical Bulletin, erschienen am 01.01.2023. Verfasst von Hangtian Zhou und 10 weiteren Autor:innen. Beteiligte Einrichtung: Anhui Clinical and Preclinical Key Laboratory of Respiratory Disease, Molecular Diagnosis Center, the Department of Pulmonary and Critical Care Medic…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 35 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lung cancer is the leading cause of cancer-related deaths worldwide, synthesizing and screening of novel anti-cancer drugs provides an alternative therapeutic strategy for renewal of the chemotherapy regimens against lung cancer. To this end, several compounds were synthesized based on the modification of the original myricetin, and their anti-tumor activity against the human non-small cell lung cancer (NSCLC) A549 cells were measured. Among the myricetin derivatives, S4-10 has displayed the highest antitumor efficacy in dose-dependent manner. The proliferation of A549 cells were significantly attenuated by given 6 µM of S4-10 both in vitro and in vivo. Further, the treatment of S4-10 also results in the inhibition of cell migration and invasiveness and the induction of cell apoptosis and G2 cycle arrest of A549 cells. Moreover, we found that S4-10 inhibits the progression of A549 cells through the sterol biosynthetic-cell apoptosis axis. These findings shed the light of developing S4-10 as a promising treatment agent for NSCLC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsHumansA549 CellsCell Cycle CheckpointsApoptosisCell ProliferationCell Line, TumorCell CycleFlavonoids

Stichwörter der Autor:innen

S4-10chemotherapymyricetinnon-small cell lung cancer

Substanzen

myricetinFlavonoids

Autor:innen und Institutionen

  • Anhui Clinical and Preclinical Key Laboratory of Respiratory Disease, Molecular Diagnosis Center, the Department of Pulmonary and Critical Care Medicine, First Affiliated Hospital, Bengbu Medical College.
  • Department of Hand Surgery, Huashan Hospital, Fudan University.
  • Department of Basic Medical College, Bengbu Medical College.
  • Anhui Key Laboratory of Infection and Immunity of Bengbu Medical College.
  • Research and Development Center for Fine Chemicals, Guizhou University.

Zitieren

APA

Zhou, H., Xu, L., Shi, Y., Gu, S., Wu, N., Liu, F., Huang, Y., Qian, Z., Xue, W., Wang, X., & Chen, F. (2023). A Novel Myricetin Derivative with Anti-cancer Properties Induces Cell Cycle Arrest and Apoptosis in A549 Cells. Biological and Pharmaceutical Bulletin, 46(1), 42-51. https://doi.org/10.1248/bpb.b22-00483

Vancouver

Zhou H, Xu L, Shi Y, Gu S, Wu N, Liu F, et al. A Novel Myricetin Derivative with Anti-cancer Properties Induces Cell Cycle Arrest and Apoptosis in A549 Cells. Biological and Pharmaceutical Bulletin. 2023;46(1):42-51. doi:10.1248/bpb.b22-00483

BibTeX
@article{Zhou2023,
  author = {Zhou, Hangtian and Xu, Lingling and Shi, Yan and Gu, Shihui and Wu, Nan and Liu, Fei and Huang, Yinjiu and Qian, Zhongqing and Xue, Wei and Wang, Xiaojing and Chen, Fuliang},
  title = {A Novel Myricetin Derivative with Anti-cancer Properties Induces Cell Cycle Arrest and Apoptosis in A549 Cells},
  journal = {Biological and Pharmaceutical Bulletin},
  year = {2023},
  volume = {46},
  number = {1},
  pages = {42--51},
  doi = {10.1248/bpb.b22-00483}
}
Kostenlos starten →